Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Zevalin Plus BuCyE High-dose Therapy in B-cell Non-Hodgkin's Lymphoma

This study has been completed.
Sponsor:
Collaborator:
Schering-Plough
Information provided by (Responsible Party):
Cheolwon Suh, Asan Medical Center
ClinicalTrials.gov Identifier:
NCT00336843
First received: June 13, 2006
Last updated: February 13, 2016
Last verified: February 2016